JMD: Dr Rajesh Jain
Revenue: Rs 253 crore (Bioscience)
Panacea Biotec is the first company in the world to develop fully-liquid pentavalent vaccine Easyfive-TT (HepB-Hib-DTwP). It played a pivotal role in the eradication of polio from India and many other countries by supplying more than 10 billion doses of oral polio vaccine to Government of India and UNICEF.
It is also the first Indian company to develop generic nanoparticle-based paclitaxel ‘PacliALL' for treating breast cancer and launched the product in India at ~50 percent lower cost. Granted patent in Russian Federation on a new formulation. Panacea was awarded the ‘Top 50 Innovator Company of India Award' in 2016 based on its contribution in R&D and patents filings by Thomson Reuters.
Panacea's net turnover of pharmaceutical formulations business has grown at a CAGR of around 7.6 per cent from Rs 2,398.8 million in FY2009-10 to Rs 3,727.0 million in FY2015-16.
The net turnover from domestic pharmaceutical formulation business has grown at a CAGR of around 6.7 percent from Rs 2,105.9 million in FY2009-10 to Rs 3,107.3 million in FY2015-16 with diabetes and cardiology and transplantation segments being the top two therapeutic segments, contributing around 28 percent and 29 percent respectively during the year under review.